Published in Breast Cancer Res on January 01, 2007
A kinetic-based sigmoidal model for the polymerase chain reaction and its application to high-capacity absolute quantitative real-time PCR. BMC Biotechnol (2008) 2.60
Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. Am J Pathol (2010) 1.73
RCP is a human breast cancer-promoting gene with Ras-activating function. J Clin Invest (2009) 1.71
Genome-wide expression patterns of invasion front, inner tumor mass and surrounding normal epithelium of colorectal tumors. Mol Cancer (2007) 1.06
YB-1, the E2F pathway, and regulation of tumor cell growth. J Natl Cancer Inst (2011) 1.04
Gene arrays for diagnosis, prognosis and treatment of breast cancer metastasis. Clin Exp Metastasis (2007) 0.94
Prediction of breast cancer metastasis by genomic profiling: where do we stand? Clin Exp Metastasis (2009) 0.92
Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. Eur J Clin Pharmacol (2008) 0.86
Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer. Genet Epigenet (2015) 0.85
Towards mechanism classifiers: expression-anchored Gene Ontology signature predicts clinical outcome in lung adenocarcinoma patients. AMIA Annu Symp Proc (2012) 0.84
Gene expression profile analysis of t1 and t2 breast cancer reveals different activation pathways. ISRN Oncol (2013) 0.81
Discovery of EST-SSRs in lung cancer: tagged ESTs with SSRs lead to differential amino acid and protein expression patterns in cancerous tissues. PLoS One (2011) 0.78
Enumerating the gene sets in breast cancer, a "direct" alternative to hierarchical clustering. BMC Genomics (2010) 0.77
Annotating breast cancer microarray samples using ontologies. AMIA Annu Symp Proc (2008) 0.75
Molecular portraits of human breast tumours. Nature (2000) 94.14
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet (2005) 29.45
Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet (2000) 24.22
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell (2002) 17.32
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol (2006) 16.25
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
Concordance among gene-expression-based predictors for breast cancer. N Engl J Med (2006) 13.50
Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A (2002) 12.68
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A (2005) 10.85
Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A (2004) 9.42
Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol (2004) 9.38
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res (2001) 8.34
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res (2006) 8.08
A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell (2004) 8.06
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A (2003) 7.57
Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med (2006) 7.45
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol (2006) 7.24
Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med (2001) 6.66
Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A (2003) 6.35
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell (2003) 6.11
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet (2003) 5.40
Exploring the conditional coregulation of yeast gene expression through fuzzy k-means clustering. Genome Biol (2002) 4.24
Genetic regulators of large-scale transcriptional signatures in cancer. Nat Genet (2006) 3.96
Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet (2003) 3.78
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol (2004) 2.95
New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res (2001) 2.69
A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res (2005) 2.65
Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol (2006) 2.48
Identification of cell cycle-regulated genes in fission yeast. Mol Biol Cell (2004) 2.29
Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci U S A (2002) 2.15
Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer. Cancer Res (2006) 1.83
Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol (2005) 1.73
Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res (2006) 1.72
p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. J Biol Chem (2004) 1.70
Genomic and expression analysis of the 8p11-12 amplicon in human breast cancer cell lines. Cancer Res (2004) 1.65
Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res (2005) 1.46
Predicting continuous values of prognostic markers in breast cancer from microarray gene expression profiles. Mol Cancer Ther (2004) 1.07
Genetic variation in putative regulatory loci controlling gene expression in breast cancer. Proc Natl Acad Sci U S A (2006) 1.03
DNA microarrays: more than gene expression. Nature (2005) 0.87
A global map of p53 transcription-factor binding sites in the human genome. Cell (2006) 20.65
International network of cancer genome projects. Nature (2010) 20.35
Genome-wide analysis of mammalian promoter architecture and evolution. Nat Genet (2006) 17.19
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A (2003) 13.00
An oestrogen-receptor-alpha-bound human chromatin interactome. Nature (2009) 12.16
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res (2006) 8.08
Gene identification signature (GIS) analysis for transcriptome characterization and genome annotation. Nat Methods (2005) 7.87
Mapping human genetic diversity in Asia. Science (2009) 7.40
Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev (2007) 6.71
Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet (2003) 5.99
Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet (2007) 5.85
RNA viral community in human feces: prevalence of plant pathogenic viruses. PLoS Biol (2006) 4.93
Next-generation DNA sequencing of paired-end tags (PET) for transcriptome and genome analyses. Genome Res (2009) 4.47
Evolution of the mammalian transcription factor binding repertoire via transposable elements. Genome Res (2008) 3.76
Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst (2002) 3.40
Transcriptome profiling of human and murine ESCs identifies divergent paths required to maintain the stem cell state. Stem Cells (2005) 3.16
Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome Biol (2004) 2.77
Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res (2006) 2.69
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet (2010) 2.62
Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression. Nat Biotechnol (2005) 2.51
Tracking the evolution of the SARS coronavirus using high-throughput, high-density resequencing arrays. Genome Res (2004) 2.47
DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell (2008) 2.46
Regulation of estrogen receptor-mediated long range transcription via evolutionarily conserved distal response elements. J Biol Chem (2008) 2.34
Transcriptome analysis of zebrafish embryogenesis using microarrays. PLoS Genet (2005) 2.32
Identification of cell cycle-regulated genes in fission yeast. Mol Biol Cell (2004) 2.29
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 2.21
Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci U S A (2002) 2.15
Early B cell factor 1 regulates B cell gene networks by activation, repression, and transcription- independent poising of chromatin. Immunity (2010) 2.08
Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci U S A (2005) 2.07
Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res (2002) 2.04
Integrative model of genomic factors for determining binding site selection by estrogen receptor-α. Mol Syst Biol (2010) 2.04
Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res (2006) 2.02
p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. J Biol Chem (2004) 1.70
Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays. J Mol Diagn (2002) 1.67
Comprehensive long-span paired-end-tag mapping reveals characteristic patterns of structural variations in epithelial cancer genomes. Genome Res (2011) 1.67
JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer. Breast Cancer Res (2012) 1.67
5' Long serial analysis of gene expression (LongSAGE) and 3' LongSAGE for transcriptome characterization and genome annotation. Proc Natl Acad Sci U S A (2004) 1.64
GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet (2011) 1.58
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol (2008) 1.57
Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: correlation to human disease. Cancer Res (2004) 1.57
The Archon Genomics X PRIZE for whole human genome sequencing. Nat Genet (2010) 1.56
Estrogen receptor regulation of carbonic anhydrase XII through a distal enhancer in breast cancer. Cancer Res (2008) 1.55
Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state. Mol Syst Biol (2011) 1.55
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol (2005) 1.51
Systematic deletion analysis of fission yeast protein kinases. Eukaryot Cell (2005) 1.51
Dragon ERE Finder version 2: A tool for accurate detection and analysis of estrogen response elements in vertebrate genomes. Nucleic Acids Res (2003) 1.49
Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology (2005) 1.48
Regulation of transcription through acetylation of H3K122 on the lateral surface of the histone octamer. Cell (2013) 1.40
De-novo identification of PPARgamma/RXR binding sites and direct targets during adipogenesis. PLoS One (2009) 1.39
Prevalence and spectrum of p53 mutations associated with smoking in breast cancer. Cancer Res (2002) 1.38
Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. Cancer Res (2005) 1.38
Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene (2005) 1.36
The feasibility of using fine needle aspiration from primary breast cancers for cDNA microarray analyses. Clin Cancer Res (2002) 1.35
Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res (2002) 1.34
Optimal gene expression analysis by microarrays. Cancer Cell (2002) 1.34
Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res (2002) 1.32
Genetic background is an important determinant of metastatic potential. Nat Genet (2003) 1.31
Transcriptional consequences of genomic structural aberrations in breast cancer. Genome Res (2011) 1.30
Linkage disequilibrium mapping of CHEK2: common variation and breast cancer risk. PLoS Med (2006) 1.23
Mutational dynamics of the SARS coronavirus in cell culture and human populations isolated in 2003. BMC Infect Dis (2004) 1.21
Multi-variant pathway association analysis reveals the importance of genetic determinants of estrogen metabolism in breast and endometrial cancer susceptibility. PLoS Genet (2010) 1.19
Multiplatform genome-wide identification and modeling of functional human estrogen receptor binding sites. Genome Biol (2006) 1.17
HER-2/neu and topoisomerase IIalpha in breast cancer. Breast Cancer Res Treat (2003) 1.15
A gene harvest revealing the archeology and complexity of human disease. Nat Genet (2007) 1.15
Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Res (2007) 1.11
Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer. Curr Cancer Drug Targets (2006) 1.11
SARS transmission pattern in Singapore reassessed by viral sequence variation analysis. PLoS Med (2005) 1.11
Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. BMC Med (2006) 1.08
Identification of Src transformation fingerprint in human colon cancer. Oncogene (2002) 1.07
Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors. Oncogene (2005) 1.06
Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Mol Cancer Ther (2004) 1.05
Detection of severe acute respiratory syndrome coronavirus in blood of infected patients. J Clin Microbiol (2004) 1.04
Structural mutations in cancer: mechanistic and functional insights. Trends Genet (2012) 1.03
Integrative genomics of gene and metabolic regulation by estrogen receptors α and β, and their coregulators. Mol Syst Biol (2013) 1.03
Global profiling of DNA replication timing and efficiency reveals that efficient replication/firing occurs late during S-phase in S. pombe. PLoS One (2007) 1.03
Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach. Hepatology (2004) 1.02
Genome-wide expression profiling; a panel of mouse tissues discloses novel biological functions of liver X receptors in adrenals. J Mol Endocrinol (2004) 1.01
A bioinformatics-based strategy identifies c-Myc and Cdc25A as candidates for the Apmt mammary tumor latency modifiers. Genome Res (2002) 1.01
Zebrafish whole-adult-organism chemogenomics for large-scale predictive and discovery chemical biology. PLoS Genet (2008) 1.00
ESR1 and EGF genetic variation in relation to breast cancer risk and survival. Breast Cancer Res (2008) 1.00
Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Oncogene (2002) 0.98
Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog (2003) 0.97
Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer. EMBO Mol Med (2011) 0.95
Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma. Neoplasia (2010) 0.94
Heterogeneous epigenetic regulation of TIMP3 in prostate cancer. Epigenetics (2012) 0.94
Transcriptome kinetics of arsenic-induced adaptive response in zebrafish liver. Physiol Genomics (2006) 0.94
Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study. Breast Cancer Res (2006) 0.93
cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene. Carcinogenesis (2002) 0.93
A human in vitro model system for investigating genome-wide host responses to SARS coronavirus infection. BMC Infect Dis (2004) 0.93
Primate-specific endogenous cis-antisense transcription in the human 5q31 protocadherin gene cluster. J Mol Evol (2005) 0.93
Interrogating the transcriptome. Trends Biotechnol (2004) 0.92
Multi-tissue gene-expression analysis in a mouse model of thyroid hormone resistance. Genome Biol (2004) 0.90
BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3. Cancer Res (2004) 0.89
Long span DNA paired-end-tag (DNA-PET) sequencing strategy for the interrogation of genomic structural mutations and fusion-point-guided reconstruction of amplicons. PLoS One (2012) 0.89
BEARR: Batch Extraction and Analysis of cis-Regulatory Regions. Nucleic Acids Res (2004) 0.88
Effect of ATM, CHEK2 and ERBB2 TAGSNPs and haplotypes on endometrial cancer risk. Hum Mol Genet (2006) 0.87
Liver X receptors regulate adrenal steroidogenesis and hypothalamic-pituitary-adrenal feedback. Mol Endocrinol (2006) 0.87
HER-2/neu and topoisomerase IIalpha--simultaneous drug targets in cancer. Comb Chem High Throughput Screen (2003) 0.86